Consumer representatives Carl Schmid, Amy Killelea, and Deborah Steinberg presented data on prior authorization and prescription drugs to the NAIC Prescripion Drug (B) Working Group, including showing that 31 percent of first fills of brand name Rx’s were rejected due to utilization management in exchange plans.
Carl Schmid of the HIV+Hepatitis Policy Institute joins Hannah Lynch, Associate Director, U.S. Public Policy at UCB, to discuss how we can evolve the healthcare system to better serve people living with severe diseases and help them overcome access barriers.
At the NAIC meeting, Carl Schmid and colleagues present consumer representatives’ report on investigation of how insurers are implementing ACA preventive service requirements, including PrEP, and urge state regulators to take action to ensure insurers are compliant with the law.
NAIC Consumer Reps. Carl Schmid and Deb Darcy discuss barriers consumers face in accessing healthcare through the high number of prior authorizations and the appeals and denials process, and request the NAIC develop a workstream that improves data collection, and consumer awareness of the appeals process, update model laws, and better enforcement of federal and state laws and regulations.
NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.